LAG3 and neoplasm: (117) found extensive co-expression of LAG-3 and PD-1 on tumor-infiltrating CD8(+) and CD4(+) T cells, and used anti-LAG-3/PD-1 dual antibodies to treat mice already resistant to single antibody treatment, and found that this combination cured most of the mice.